Oaktree Acquisition Corp. III Life Sciences appoints David A. Berry as independent director

Oaktree Acquisition Corp. III Life Sciences

Appointed Oct 17, 2025 as Class II director on audit, nominating, and compensation committees; deemed independent under Nasdaq and Rule 10A-3.
Co-founder & Managing Partner of Averin Capital (since May 2025); former Partner/GP at Flagship Pioneering (2005-2025); founder/CEO of Valo Health.
No cash compensation; eligible to invest non-controlling minority interest in Oaktree Acquisition Holdings III LS, consistent with other independent directors.
Will execute standard Letter Agreement and Indemnity Agreement on same terms as directors/officers from IPO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.